Posttransplant lymphoproliferative disorders

Research output: Chapter in Book/Report/Conference proceedingChapter

5 Citations (Scopus)

Abstract

In 1968, Starzl reported the clinical observation that transplant patients are prone to develop lymphomatous growths (1). The term posttransplant lymphoproliferative disorder (PTLD) is applied to a group of lymphoproliferative disorders arising in a pharmacologically immunocompromised host after solid-organ or allogeneic stem cell transplantation. Among iatrogenic immune deficiency states, PTLD is quite common (2). PTLDs are the most serious complications of chronic immunosuppression and represent one of the most commonly observed fatal consequences of immunosuppression in patients undergoing solid-organ transplantation. PTLDs are the most common malignancy complicating organ transplantation after nonmelanomatous skin cancer and in situ cervical cancer (3). PTLDs represent 21% of all malignancies versus 5% of malignancies in immunocompetent patients (not sure what this means?). Clinically, this group of disorders might be slow growing or aggressive, localized or mulitcentric, associated with symptoms or no symptoms, more characteristically involve extranodal sites, and disease in the allograft organ is more common (4-6). The biology, diagnosis, and management of this heterogeneous group of disorders have nuances that are different than other non-Hodgkin's lymphomas. The issues in evaluating published PTLD data involve multiple variables, including Epstein-Barr virus (EBV) serostatus prior to the organ transplant in the donor and the recipient, stages of disease, types and doses of immunosuppressive agents utilized in the course of the transplant, initial PTLD management strategies (surgery, immunosuppression reduction strategies), types of treatment (rituximab as monotherapy, etc.), the timing and incorporation of treatment regimens, the timing of treatment after the PTLD diagnosis, presentation from the time of transplant, pathology reporting, locations of extranodal involvement, and comorbid conditions [other vital organ involvement, performance status, active infections (Cytomegalovirus (CMV), fungal), etc. Two International Consensus Development meetings were held in 1997 and 1998 that addressed different issues in PTLD in working groups, recommended management guidelines, and set the stage for future directions (7). This review will focus on adult solid-organ PTLD.

Original languageEnglish (US)
Title of host publicationRare Hematological Malignancies
PublisherSpringer US
Pages273-292
Number of pages20
ISBN (Print)9780387737430
DOIs
StatePublished - 2008

Fingerprint

Lymphoproliferative Disorders
Immunosuppression
Transplants
Organ Transplantation
Neoplasms
Mycoses
Cytomegalovirus Infections
Immunocompromised Host
Stem Cell Transplantation
Skin Neoplasms
Immunosuppressive Agents
Human Herpesvirus 4
Uterine Cervical Neoplasms
Non-Hodgkin's Lymphoma
Allografts
Consensus
Therapeutics
Tissue Donors
Guidelines
Pathology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Habermann, T. M. (2008). Posttransplant lymphoproliferative disorders. In Rare Hematological Malignancies (pp. 273-292). Springer US. https://doi.org/10.1007/978-0-387-73744-7_12

Posttransplant lymphoproliferative disorders. / Habermann, Thomas Matthew.

Rare Hematological Malignancies. Springer US, 2008. p. 273-292.

Research output: Chapter in Book/Report/Conference proceedingChapter

Habermann, TM 2008, Posttransplant lymphoproliferative disorders. in Rare Hematological Malignancies. Springer US, pp. 273-292. https://doi.org/10.1007/978-0-387-73744-7_12
Habermann TM. Posttransplant lymphoproliferative disorders. In Rare Hematological Malignancies. Springer US. 2008. p. 273-292 https://doi.org/10.1007/978-0-387-73744-7_12
Habermann, Thomas Matthew. / Posttransplant lymphoproliferative disorders. Rare Hematological Malignancies. Springer US, 2008. pp. 273-292
@inbook{fb2a24b1047e49d285ba5757ba5ad14f,
title = "Posttransplant lymphoproliferative disorders",
abstract = "In 1968, Starzl reported the clinical observation that transplant patients are prone to develop lymphomatous growths (1). The term posttransplant lymphoproliferative disorder (PTLD) is applied to a group of lymphoproliferative disorders arising in a pharmacologically immunocompromised host after solid-organ or allogeneic stem cell transplantation. Among iatrogenic immune deficiency states, PTLD is quite common (2). PTLDs are the most serious complications of chronic immunosuppression and represent one of the most commonly observed fatal consequences of immunosuppression in patients undergoing solid-organ transplantation. PTLDs are the most common malignancy complicating organ transplantation after nonmelanomatous skin cancer and in situ cervical cancer (3). PTLDs represent 21{\%} of all malignancies versus 5{\%} of malignancies in immunocompetent patients (not sure what this means?). Clinically, this group of disorders might be slow growing or aggressive, localized or mulitcentric, associated with symptoms or no symptoms, more characteristically involve extranodal sites, and disease in the allograft organ is more common (4-6). The biology, diagnosis, and management of this heterogeneous group of disorders have nuances that are different than other non-Hodgkin's lymphomas. The issues in evaluating published PTLD data involve multiple variables, including Epstein-Barr virus (EBV) serostatus prior to the organ transplant in the donor and the recipient, stages of disease, types and doses of immunosuppressive agents utilized in the course of the transplant, initial PTLD management strategies (surgery, immunosuppression reduction strategies), types of treatment (rituximab as monotherapy, etc.), the timing and incorporation of treatment regimens, the timing of treatment after the PTLD diagnosis, presentation from the time of transplant, pathology reporting, locations of extranodal involvement, and comorbid conditions [other vital organ involvement, performance status, active infections (Cytomegalovirus (CMV), fungal), etc. Two International Consensus Development meetings were held in 1997 and 1998 that addressed different issues in PTLD in working groups, recommended management guidelines, and set the stage for future directions (7). This review will focus on adult solid-organ PTLD.",
author = "Habermann, {Thomas Matthew}",
year = "2008",
doi = "10.1007/978-0-387-73744-7_12",
language = "English (US)",
isbn = "9780387737430",
pages = "273--292",
booktitle = "Rare Hematological Malignancies",
publisher = "Springer US",

}

TY - CHAP

T1 - Posttransplant lymphoproliferative disorders

AU - Habermann, Thomas Matthew

PY - 2008

Y1 - 2008

N2 - In 1968, Starzl reported the clinical observation that transplant patients are prone to develop lymphomatous growths (1). The term posttransplant lymphoproliferative disorder (PTLD) is applied to a group of lymphoproliferative disorders arising in a pharmacologically immunocompromised host after solid-organ or allogeneic stem cell transplantation. Among iatrogenic immune deficiency states, PTLD is quite common (2). PTLDs are the most serious complications of chronic immunosuppression and represent one of the most commonly observed fatal consequences of immunosuppression in patients undergoing solid-organ transplantation. PTLDs are the most common malignancy complicating organ transplantation after nonmelanomatous skin cancer and in situ cervical cancer (3). PTLDs represent 21% of all malignancies versus 5% of malignancies in immunocompetent patients (not sure what this means?). Clinically, this group of disorders might be slow growing or aggressive, localized or mulitcentric, associated with symptoms or no symptoms, more characteristically involve extranodal sites, and disease in the allograft organ is more common (4-6). The biology, diagnosis, and management of this heterogeneous group of disorders have nuances that are different than other non-Hodgkin's lymphomas. The issues in evaluating published PTLD data involve multiple variables, including Epstein-Barr virus (EBV) serostatus prior to the organ transplant in the donor and the recipient, stages of disease, types and doses of immunosuppressive agents utilized in the course of the transplant, initial PTLD management strategies (surgery, immunosuppression reduction strategies), types of treatment (rituximab as monotherapy, etc.), the timing and incorporation of treatment regimens, the timing of treatment after the PTLD diagnosis, presentation from the time of transplant, pathology reporting, locations of extranodal involvement, and comorbid conditions [other vital organ involvement, performance status, active infections (Cytomegalovirus (CMV), fungal), etc. Two International Consensus Development meetings were held in 1997 and 1998 that addressed different issues in PTLD in working groups, recommended management guidelines, and set the stage for future directions (7). This review will focus on adult solid-organ PTLD.

AB - In 1968, Starzl reported the clinical observation that transplant patients are prone to develop lymphomatous growths (1). The term posttransplant lymphoproliferative disorder (PTLD) is applied to a group of lymphoproliferative disorders arising in a pharmacologically immunocompromised host after solid-organ or allogeneic stem cell transplantation. Among iatrogenic immune deficiency states, PTLD is quite common (2). PTLDs are the most serious complications of chronic immunosuppression and represent one of the most commonly observed fatal consequences of immunosuppression in patients undergoing solid-organ transplantation. PTLDs are the most common malignancy complicating organ transplantation after nonmelanomatous skin cancer and in situ cervical cancer (3). PTLDs represent 21% of all malignancies versus 5% of malignancies in immunocompetent patients (not sure what this means?). Clinically, this group of disorders might be slow growing or aggressive, localized or mulitcentric, associated with symptoms or no symptoms, more characteristically involve extranodal sites, and disease in the allograft organ is more common (4-6). The biology, diagnosis, and management of this heterogeneous group of disorders have nuances that are different than other non-Hodgkin's lymphomas. The issues in evaluating published PTLD data involve multiple variables, including Epstein-Barr virus (EBV) serostatus prior to the organ transplant in the donor and the recipient, stages of disease, types and doses of immunosuppressive agents utilized in the course of the transplant, initial PTLD management strategies (surgery, immunosuppression reduction strategies), types of treatment (rituximab as monotherapy, etc.), the timing and incorporation of treatment regimens, the timing of treatment after the PTLD diagnosis, presentation from the time of transplant, pathology reporting, locations of extranodal involvement, and comorbid conditions [other vital organ involvement, performance status, active infections (Cytomegalovirus (CMV), fungal), etc. Two International Consensus Development meetings were held in 1997 and 1998 that addressed different issues in PTLD in working groups, recommended management guidelines, and set the stage for future directions (7). This review will focus on adult solid-organ PTLD.

UR - http://www.scopus.com/inward/record.url?scp=84892819512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892819512&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-73744-7_12

DO - 10.1007/978-0-387-73744-7_12

M3 - Chapter

C2 - 18283791

AN - SCOPUS:84892819512

SN - 9780387737430

SP - 273

EP - 292

BT - Rare Hematological Malignancies

PB - Springer US

ER -